Sanofi Strengthens Immunology Pipeline with DR-0201 Acquisition

Sanofi ( (SNY) ) has issued an update.

In May 2025, Sanofi announced the completion of its acquisition of DR-0201, a bispecific myeloid cell engager from Dren Bio, Inc., for $600 million with potential future payments of $1.3 billion. This acquisition enhances Sanofi’s immunology pipeline and supports its ambition to lead in the immunology sector. Additionally, Sanofi reported that its drug Beyfortus showed a public health advantage in a real-world comparison of infant versus maternal RSV immunization programs. Furthermore, Sanofi’s Itepekimab met the primary endpoint in one of two COPD phase 3 studies, indicating progress in its respiratory disease treatment pipeline.

The most recent analyst rating on (SNY) stock is a Hold with a $67.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.

Spark’s Take on SNY Stock

According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.

Sanofi demonstrates strong financial stability and strategic growth in key areas like Dupixent, supported by a solid earnings report. Despite some technical weaknesses and cash flow concerns, the company’s valuation remains reasonable, making it a potentially attractive investment with manageable risks.

To see Spark’s full report on SNY stock, click here.

More about Sanofi

Sanofi is a global healthcare company focused on transforming the practice of medicine through innovative treatments and vaccines. The company aims to improve lives by providing life-changing treatment options and life-saving vaccine protection, with a strong emphasis on sustainability and social responsibility. Sanofi is publicly traded on EURONEXT and NASDAQ.

Average Trading Volume: 2,917,883

Technical Sentiment Signal: Buy

Current Market Cap: $127.4B

For a thorough assessment of SNY stock, go to TipRanks’ Stock Analysis page.